GLP-1 weight drugs edge toward PBS — what's holding it up

What just happened

Health Minister Mark Butler has confirmed that price negotiations with Novo Nordisk and Eli Lilly are ongoing and that an agreed price is the primary barrier to listing GLP-1 weight-management medications on the PBS. Semaglutide (Wegovy) has TGA approval for weight management and cardiovascular disease risk reduction in eligible adults. But TGA approval and PBS listing are two different things — and without a PBS listing, the out-of-pocket cost for most Australians is $200 to $700 per month.

That price is not abstract. Around 500,000 Australians are currently using GLP-1 receptor agonists, paying out-of-pocket or through workplace health programs. At the lower end, $200 a month is $2,400 a year. At the higher end, $700 a month is $8,400 a year. For a medication that requires ongoing use to maintain its effect — stopping semaglutide typically results in weight regain within a year — this is not a one-time cost. It compounds.

Dr Tim Senior, the RACGP’s Poverty and Health Chair, has put it directly: obesity disproportionately affects lower-income communities, and the cost of this medication makes it “completely inaccessible for many Australians.” The people who most need the medication are often the ones who can least afford to pay for it privately.

Both-and

The case for PBS listing

The clinical evidence for semaglutide in obesity management is strong. The STEP trial program showed consistent weight loss in the range of 12–15% of body weight in adults without type 2 diabetes, with maintained reductions in cardiovascular event rates in the SELECT trial (20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease). This is not a cosmetic medication — it addresses a metabolic condition with downstream effects on heart disease, sleep apnoea, joint disease, and cancer risk.

The equity argument for listing is equally straightforward: if the clinical evidence meets the threshold for TGA approval and PBAC review, restricting access to those who can afford $5,000–6,000 a year creates a two-tiered system. Affluent Australians with obesity access effective, well-studied treatment. Lower-income Australians, who carry a disproportionate burden of obesity and its complications, go without. The PBS exists precisely to prevent this kind of access stratification.

The government’s own 90%-bulk-billing target recognises that general practice access should not depend on income. Subsidising a chronic disease treatment that demonstrably reduces cardiovascular events — and associated hospital admissions — is not inconsistent with that framing.

The contested territory

Price negotiations for GLP-1 medications are complex, and not only because the drugs are expensive. The PBAC reviews cost-effectiveness against a defined threshold — typically a cost-per-QALY (quality-adjusted life year) that the Australian government is willing to pay. GLP-1 medications for obesity are at the premium end of that equation, and Novo Nordisk’s list price reflects that.

There is also a question of prescribing pathway. If GLP-1 medications are PBS-listed without clear prescribing criteria, demand could significantly outpace supply — as happened in the United States, where semaglutide shortages followed its rapid uptake. The RACGP has consistently argued that general practice must be central to prescribing and monitoring, not routed through specialist-only pathways. A tiered approach — GP initiation for patients meeting defined criteria, with specialist referral for complex cases — would be more equitable and more consistent with how chronic disease is already managed in Australia.

The contested question is also whether the PBS listing, if it comes, will include criteria tight enough to target the patients with the greatest need and the strongest evidence base, or whether it will be broad enough to create budget exposure the government is unwilling to accept. That tension is exactly what the price negotiations are navigating.

What is not contested

The TGA’s approval decision. The clinical evidence behind it is robust, and the drug’s safety profile is well-characterised — the most common side effects are gastrointestinal (nausea, vomiting, diarrhoea), generally dose-dependent and resolving over the first weeks of use. There are important contraindications (history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pregnancy or breastfeeding), but the approval covers a patient population for whom the cardiovascular and metabolic benefits are well-supported.

The need for monitoring is also not contested. Semaglutide is not a stand-alone intervention — it is most effective alongside dietary and behavioural support, and ongoing prescribing requires regular review of weight, blood pressure, renal function, and any emerging side effects. This is general practice work. It is not a specialist-exclusive function.

My two cents

If you are already taking a GLP-1 medication out-of-pocket, the most useful thing this week is to make sure you have an arrangement for regular GP review — weight check, blood pressure, kidney function, and a conversation about what maintenance looks like long-term.

If you are considering it and cost is the barrier, it is worth a conversation with your GP about whether you meet the type 2 diabetes PBS criteria for Ozempic (the lower-dose formulation), or whether there are other weight-management pathways — structured GP-led programs, some of which attract Medicare rebates — that might be available while the PBS listing question is unresolved.

If a PBS listing arrives in the next 12 months, the prescribing criteria will matter significantly. What the RACGP is advocating for — GP-led, with defined eligibility criteria and good clinical evidence behind it — would make access substantially more equitable than a specialist-only model.

Verdict: maybe — watch this space. No PBS listing yet, price talks ongoing, no confirmed timeline. Worth knowing where things stand.

---

Sources cited

1. Price talks continue as Health Minister pushes for GLP-1 PBS access. RACGP newsGP, August 2026. https://www1.racgp.org.au/newsgp
2. Prescription medicines — semaglutide (Wegovy). Therapeutic Goods Administration. https://www.tga.gov.au/products/medicines/prescription-medicines
3. RACGP position — obesity management in general practice. https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/obesity